| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Spectroscopy | 12 | 2011 | 346 | 2.010 |
Why?
|
| Magnetic Resonance Imaging | 26 | 2015 | 2222 | 1.950 |
Why?
|
| Brain | 16 | 2015 | 2175 | 1.430 |
Why?
|
| Cerebrovascular Circulation | 8 | 2011 | 296 | 0.910 |
Why?
|
| Hemosiderin | 4 | 2011 | 11 | 0.850 |
Why?
|
| Ferritins | 4 | 2011 | 49 | 0.840 |
Why?
|
| Image Enhancement | 5 | 2010 | 143 | 0.830 |
Why?
|
| Hippocampus | 7 | 2012 | 471 | 0.810 |
Why?
|
| Cerebrovascular Disorders | 3 | 2010 | 182 | 0.760 |
Why?
|
| Artifacts | 3 | 2009 | 125 | 0.740 |
Why?
|
| Iron Overload | 3 | 2010 | 28 | 0.720 |
Why?
|
| Blood Flow Velocity | 2 | 2011 | 172 | 0.720 |
Why?
|
| Arteries | 2 | 2011 | 108 | 0.710 |
Why?
|
| Cognition Disorders | 3 | 2009 | 342 | 0.630 |
Why?
|
| beta-Thalassemia | 2 | 2010 | 17 | 0.630 |
Why?
|
| Algorithms | 9 | 2011 | 1194 | 0.610 |
Why?
|
| Iron | 3 | 2011 | 197 | 0.570 |
Why?
|
| Weightlessness Simulation | 1 | 2015 | 6 | 0.540 |
Why?
|
| Head-Down Tilt | 1 | 2015 | 7 | 0.540 |
Why?
|
| Liver | 4 | 2010 | 1118 | 0.530 |
Why?
|
| Space Flight | 1 | 2015 | 40 | 0.500 |
Why?
|
| Echo-Planar Imaging | 2 | 2011 | 17 | 0.480 |
Why?
|
| Cerebral Infarction | 2 | 2012 | 103 | 0.480 |
Why?
|
| Memory Disorders | 2 | 2012 | 111 | 0.470 |
Why?
|
| Image Interpretation, Computer-Assisted | 4 | 2010 | 237 | 0.460 |
Why?
|
| Biomarkers, Tumor | 3 | 2006 | 508 | 0.430 |
Why?
|
| Electroencephalography | 3 | 2009 | 418 | 0.430 |
Why?
|
| Sensitivity and Specificity | 12 | 2010 | 1753 | 0.420 |
Why?
|
| Reproducibility of Results | 12 | 2010 | 2077 | 0.400 |
Why?
|
| Geriatric Assessment | 2 | 2009 | 107 | 0.400 |
Why?
|
| Auditory Perception | 2 | 2009 | 89 | 0.400 |
Why?
|
| Metabolomics | 1 | 2011 | 28 | 0.390 |
Why?
|
| Biomarkers | 3 | 2011 | 1593 | 0.390 |
Why?
|
| Image Processing, Computer-Assisted | 8 | 2011 | 689 | 0.380 |
Why?
|
| Malaria, Cerebral | 1 | 2009 | 3 | 0.360 |
Why?
|
| Cognitive Reserve | 1 | 2009 | 6 | 0.360 |
Why?
|
| Optical Devices | 1 | 2009 | 7 | 0.360 |
Why?
|
| Head Movements | 1 | 2009 | 12 | 0.360 |
Why?
|
| Mass Spectrometry | 2 | 2011 | 284 | 0.360 |
Why?
|
| Dementia, Vascular | 1 | 2009 | 22 | 0.350 |
Why?
|
| Phosphorus Compounds | 2 | 2006 | 2 | 0.350 |
Why?
|
| Event-Related Potentials, P300 | 1 | 2009 | 1 | 0.350 |
Why?
|
| Ballistocardiography | 1 | 2009 | 2 | 0.350 |
Why?
|
| Orientation | 1 | 2009 | 31 | 0.350 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2009 | 239 | 0.340 |
Why?
|
| Signal Processing, Computer-Assisted | 3 | 2009 | 100 | 0.340 |
Why?
|
| Humans | 42 | 2015 | 68525 | 0.340 |
Why?
|
| Male | 30 | 2015 | 37281 | 0.340 |
Why?
|
| Aging | 4 | 2009 | 911 | 0.330 |
Why?
|
| Aged, 80 and over | 11 | 2012 | 4843 | 0.330 |
Why?
|
| Homeostasis | 1 | 2010 | 291 | 0.330 |
Why?
|
| Parkinsonian Disorders | 1 | 2008 | 43 | 0.330 |
Why?
|
| Phosphorylcholine | 3 | 2004 | 12 | 0.320 |
Why?
|
| Female | 30 | 2015 | 38015 | 0.320 |
Why?
|
| Ethanolamines | 3 | 2004 | 33 | 0.310 |
Why?
|
| Residence Characteristics | 2 | 2009 | 252 | 0.310 |
Why?
|
| Tibia | 1 | 2008 | 93 | 0.300 |
Why?
|
| Phosphorus | 2 | 2006 | 64 | 0.300 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2008 | 333 | 0.290 |
Why?
|
| Peptide Mapping | 1 | 2006 | 39 | 0.290 |
Why?
|
| Myocardium | 3 | 2011 | 1204 | 0.290 |
Why?
|
| Databases, Protein | 1 | 2006 | 49 | 0.280 |
Why?
|
| Computer Graphics | 1 | 2006 | 37 | 0.280 |
Why?
|
| Cohort Studies | 8 | 2010 | 2356 | 0.280 |
Why?
|
| Brain Mapping | 8 | 2009 | 531 | 0.280 |
Why?
|
| Proteome | 1 | 2006 | 87 | 0.270 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2006 | 75 | 0.270 |
Why?
|
| Aged | 17 | 2012 | 14842 | 0.260 |
Why?
|
| Brain Ischemia | 2 | 2010 | 665 | 0.260 |
Why?
|
| Lymphocytes | 2 | 2003 | 228 | 0.260 |
Why?
|
| Lactates | 1 | 2004 | 29 | 0.260 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2004 | 19 | 0.260 |
Why?
|
| User-Computer Interface | 1 | 2006 | 230 | 0.250 |
Why?
|
| Urine | 1 | 2004 | 47 | 0.250 |
Why?
|
| Pattern Recognition, Automated | 1 | 2004 | 70 | 0.250 |
Why?
|
| Principal Component Analysis | 3 | 2011 | 55 | 0.250 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2004 | 36 | 0.240 |
Why?
|
| Stroke | 4 | 2012 | 2161 | 0.240 |
Why?
|
| Software | 1 | 2006 | 418 | 0.230 |
Why?
|
| Spin Labels | 4 | 2011 | 27 | 0.230 |
Why?
|
| Organophosphates | 1 | 2002 | 7 | 0.220 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2004 | 148 | 0.220 |
Why?
|
| Neuropsychological Tests | 6 | 2009 | 517 | 0.220 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2002 | 44 | 0.210 |
Why?
|
| Phantoms, Imaging | 3 | 2011 | 189 | 0.200 |
Why?
|
| Thalassemia | 2 | 2011 | 7 | 0.190 |
Why?
|
| Hypertension | 1 | 2010 | 1531 | 0.190 |
Why?
|
| Neoplasms | 3 | 2006 | 1660 | 0.180 |
Why?
|
| Nerve Fibers, Myelinated | 2 | 2010 | 49 | 0.180 |
Why?
|
| Gene Expression Profiling | 3 | 2008 | 498 | 0.180 |
Why?
|
| New York City | 2 | 2010 | 49 | 0.180 |
Why?
|
| Atrophy | 2 | 2009 | 112 | 0.170 |
Why?
|
| Alzheimer Disease | 3 | 2008 | 563 | 0.160 |
Why?
|
| Prospective Studies | 3 | 2012 | 3702 | 0.160 |
Why?
|
| Drug Delivery Systems | 3 | 2008 | 236 | 0.150 |
Why?
|
| Blood-Brain Barrier | 2 | 2008 | 99 | 0.150 |
Why?
|
| Adult | 13 | 2011 | 21375 | 0.140 |
Why?
|
| Bed Rest | 1 | 2015 | 17 | 0.130 |
Why?
|
| Hydrazines | 2 | 2004 | 23 | 0.130 |
Why?
|
| Animals | 11 | 2011 | 20877 | 0.130 |
Why?
|
| Rats, Wistar | 2 | 2004 | 371 | 0.120 |
Why?
|
| Predictive Value of Tests | 2 | 2009 | 1465 | 0.110 |
Why?
|
| Phosphorus Isotopes | 4 | 2009 | 9 | 0.110 |
Why?
|
| Tissue Distribution | 2 | 2010 | 282 | 0.110 |
Why?
|
| Equipment Failure Analysis | 2 | 2009 | 121 | 0.110 |
Why?
|
| Follow-Up Studies | 2 | 2009 | 3256 | 0.110 |
Why?
|
| Models, Statistical | 3 | 2011 | 446 | 0.100 |
Why?
|
| Neurologic Examination | 2 | 2009 | 107 | 0.100 |
Why?
|
| Models, Biological | 2 | 2007 | 981 | 0.100 |
Why?
|
| Magnetics | 2 | 2009 | 52 | 0.100 |
Why?
|
| Risk Factors | 4 | 2010 | 5719 | 0.100 |
Why?
|
| Acoustic Stimulation | 2 | 2009 | 206 | 0.100 |
Why?
|
| Perfusion | 1 | 2011 | 131 | 0.100 |
Why?
|
| Cerebral Arteries | 2 | 2009 | 50 | 0.100 |
Why?
|
| Motion | 1 | 2011 | 24 | 0.100 |
Why?
|
| Equipment Design | 2 | 2009 | 500 | 0.100 |
Why?
|
| X-Rays | 1 | 2011 | 56 | 0.100 |
Why?
|
| Dentate Gyrus | 2 | 2007 | 13 | 0.090 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 201 | 0.090 |
Why?
|
| Young Adult | 3 | 2010 | 5708 | 0.090 |
Why?
|
| Chelation Therapy | 2 | 2011 | 17 | 0.090 |
Why?
|
| Time Factors | 4 | 2011 | 4655 | 0.090 |
Why?
|
| Rats | 4 | 2008 | 5300 | 0.090 |
Why?
|
| Middle Aged | 9 | 2009 | 21119 | 0.090 |
Why?
|
| Sound | 1 | 2009 | 16 | 0.090 |
Why?
|
| Habituation, Psychophysiologic | 1 | 2009 | 22 | 0.090 |
Why?
|
| Transducers | 1 | 2009 | 21 | 0.090 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2008 | 14 | 0.080 |
Why?
|
| United States | 2 | 2015 | 7335 | 0.080 |
Why?
|
| Caribbean Region | 1 | 2008 | 10 | 0.080 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 2008 | 5 | 0.080 |
Why?
|
| Comorbidity | 2 | 2010 | 1425 | 0.080 |
Why?
|
| Self Concept | 1 | 2009 | 132 | 0.080 |
Why?
|
| Ultrasonic Therapy | 1 | 2008 | 19 | 0.080 |
Why?
|
| Prevalence | 2 | 2010 | 1609 | 0.080 |
Why?
|
| Electrodes | 1 | 2009 | 147 | 0.080 |
Why?
|
| Adolescent | 3 | 2010 | 8903 | 0.080 |
Why?
|
| Kidney Medulla | 1 | 2008 | 17 | 0.080 |
Why?
|
| Computer-Aided Design | 1 | 2009 | 101 | 0.080 |
Why?
|
| Prognosis | 2 | 2004 | 2093 | 0.080 |
Why?
|
| Disability Evaluation | 1 | 2010 | 298 | 0.080 |
Why?
|
| Leukoaraiosis | 1 | 2008 | 14 | 0.080 |
Why?
|
| Vascular Diseases | 1 | 2008 | 94 | 0.080 |
Why?
|
| Ferric Compounds | 1 | 2008 | 45 | 0.080 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2007 | 16 | 0.080 |
Why?
|
| Sonication | 1 | 2007 | 8 | 0.080 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2008 | 77 | 0.080 |
Why?
|
| Protons | 2 | 2009 | 57 | 0.080 |
Why?
|
| Stress, Mechanical | 1 | 2008 | 208 | 0.080 |
Why?
|
| Severity of Illness Index | 2 | 2010 | 1851 | 0.080 |
Why?
|
| Mice | 5 | 2011 | 8472 | 0.070 |
Why?
|
| Olfactory Bulb | 1 | 2006 | 14 | 0.070 |
Why?
|
| Oxygen | 1 | 2009 | 386 | 0.070 |
Why?
|
| Phospholipids | 2 | 2008 | 108 | 0.070 |
Why?
|
| Gadolinium | 1 | 2007 | 88 | 0.070 |
Why?
|
| Cattle | 1 | 2008 | 475 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 329 | 0.070 |
Why?
|
| Olfaction Disorders | 1 | 2008 | 100 | 0.070 |
Why?
|
| Regression Analysis | 1 | 2008 | 737 | 0.070 |
Why?
|
| Dementia | 1 | 2008 | 158 | 0.070 |
Why?
|
| Database Management Systems | 1 | 2006 | 25 | 0.070 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2007 | 181 | 0.070 |
Why?
|
| Psychomotor Performance | 1 | 2008 | 213 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 1139 | 0.070 |
Why?
|
| Information Storage and Retrieval | 1 | 2006 | 49 | 0.070 |
Why?
|
| Amyloid beta-Peptides | 1 | 2007 | 190 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2009 | 2264 | 0.070 |
Why?
|
| Smell | 1 | 2006 | 131 | 0.070 |
Why?
|
| Homocysteine | 1 | 2005 | 26 | 0.070 |
Why?
|
| Hemoglobin E | 1 | 2005 | 2 | 0.070 |
Why?
|
| Transfusion Reaction | 1 | 2005 | 33 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2005 | 951 | 0.060 |
Why?
|
| Iron Chelating Agents | 1 | 2005 | 31 | 0.060 |
Why?
|
| Deferoxamine | 1 | 2005 | 45 | 0.060 |
Why?
|
| Fetal Death | 1 | 2004 | 49 | 0.060 |
Why?
|
| Spectrum Analysis | 1 | 2004 | 81 | 0.060 |
Why?
|
| Nanoparticles | 1 | 2008 | 254 | 0.060 |
Why?
|
| Carcinogens | 1 | 2004 | 86 | 0.060 |
Why?
|
| Databases as Topic | 1 | 2004 | 49 | 0.060 |
Why?
|
| Fetal Growth Retardation | 1 | 2004 | 56 | 0.060 |
Why?
|
| Prenatal Diagnosis | 1 | 2004 | 73 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2004 | 186 | 0.060 |
Why?
|
| Deoxyglucose | 1 | 2003 | 32 | 0.060 |
Why?
|
| Blood Pressure | 1 | 2010 | 1447 | 0.060 |
Why?
|
| Cognition | 1 | 2008 | 512 | 0.060 |
Why?
|
| Models, Genetic | 1 | 2004 | 161 | 0.060 |
Why?
|
| Gestational Age | 1 | 2004 | 389 | 0.060 |
Why?
|
| Structure-Activity Relationship | 1 | 2004 | 420 | 0.060 |
Why?
|
| Phosphocreatine | 1 | 2003 | 20 | 0.060 |
Why?
|
| Biophysical Phenomena | 1 | 2003 | 25 | 0.060 |
Why?
|
| Neuromuscular Diseases | 1 | 2003 | 14 | 0.060 |
Why?
|
| Myocardial Infarction | 1 | 2008 | 807 | 0.060 |
Why?
|
| Biophysics | 1 | 2003 | 41 | 0.060 |
Why?
|
| ROC Curve | 1 | 2004 | 392 | 0.060 |
Why?
|
| Glycerylphosphorylcholine | 1 | 2002 | 1 | 0.060 |
Why?
|
| Phosphatidylethanolamines | 1 | 2002 | 20 | 0.060 |
Why?
|
| Chi-Square Distribution | 1 | 2004 | 546 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 320 | 0.060 |
Why?
|
| Nucleotides | 1 | 2002 | 29 | 0.050 |
Why?
|
| Nucleosides | 1 | 2002 | 9 | 0.050 |
Why?
|
| Esters | 1 | 2002 | 22 | 0.050 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2002 | 85 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2004 | 303 | 0.050 |
Why?
|
| Lymphoma | 1 | 2003 | 116 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2008 | 2004 | 0.050 |
Why?
|
| Schizophrenia | 1 | 2003 | 206 | 0.050 |
Why?
|
| Muscle, Skeletal | 1 | 2004 | 396 | 0.050 |
Why?
|
| Neurons | 1 | 2007 | 881 | 0.050 |
Why?
|
| Exercise | 1 | 2007 | 657 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 1745 | 0.050 |
Why?
|
| Pregnancy | 1 | 2004 | 2331 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2002 | 1548 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 2323 | 0.040 |
Why?
|
| Reference Values | 2 | 2009 | 579 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2002 | 624 | 0.040 |
Why?
|
| New York | 2 | 2008 | 223 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2009 | 7264 | 0.040 |
Why?
|
| Linear Models | 2 | 2009 | 521 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 2002 | 561 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2009 | 1046 | 0.030 |
Why?
|
| Mice, Transgenic | 2 | 2008 | 1032 | 0.030 |
Why?
|
| Contrast Media | 2 | 2008 | 594 | 0.030 |
Why?
|
| Disease Progression | 2 | 2007 | 1037 | 0.030 |
Why?
|
| Computer Simulation | 2 | 2007 | 705 | 0.030 |
Why?
|
| Chelating Agents | 1 | 2011 | 47 | 0.020 |
Why?
|
| Cytosol | 1 | 2011 | 123 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2007 | 2790 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2011 | 205 | 0.020 |
Why?
|
| Evoked Potentials | 1 | 2009 | 61 | 0.020 |
Why?
|
| Quality Control | 1 | 2009 | 81 | 0.020 |
Why?
|
| Sulfur Hexafluoride | 1 | 2008 | 1 | 0.020 |
Why?
|
| Reaction Time | 1 | 2009 | 170 | 0.020 |
Why?
|
| Head | 1 | 2009 | 59 | 0.020 |
Why?
|
| Systole | 1 | 2008 | 149 | 0.020 |
Why?
|
| Functional Laterality | 1 | 2009 | 240 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 2008 | 48 | 0.020 |
Why?
|
| Diastole | 1 | 2008 | 161 | 0.020 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 2007 | 28 | 0.020 |
Why?
|
| Flurbiprofen | 1 | 2007 | 3 | 0.020 |
Why?
|
| Entorhinal Cortex | 1 | 2007 | 11 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2007 | 48 | 0.020 |
Why?
|
| Blood Volume | 1 | 2007 | 47 | 0.020 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2007 | 72 | 0.020 |
Why?
|
| Albumins | 1 | 2007 | 72 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2009 | 295 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2009 | 652 | 0.020 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2007 | 115 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2009 | 601 | 0.020 |
Why?
|
| Fluorocarbons | 1 | 2007 | 82 | 0.020 |
Why?
|
| Papio anubis | 1 | 2006 | 1 | 0.020 |
Why?
|
| Respiration | 1 | 2006 | 91 | 0.020 |
Why?
|
| Hydrogen | 1 | 2006 | 35 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2007 | 183 | 0.020 |
Why?
|
| Hyperhomocysteinemia | 1 | 2005 | 15 | 0.020 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2005 | 17 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 2008 | 481 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 1174 | 0.020 |
Why?
|
| Logistic Models | 1 | 2009 | 1419 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2007 | 1039 | 0.020 |
Why?
|
| Social Class | 1 | 2005 | 127 | 0.020 |
Why?
|
| Reference Standards | 1 | 2004 | 115 | 0.020 |
Why?
|
| Age Factors | 1 | 2009 | 1860 | 0.020 |
Why?
|
| Internationality | 1 | 2004 | 74 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 2008 | 738 | 0.020 |
Why?
|
| Epithelium | 1 | 2004 | 172 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 2003 | 104 | 0.010 |
Why?
|
| Ovary | 1 | 2004 | 99 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2004 | 177 | 0.010 |
Why?
|
| Research | 1 | 2004 | 214 | 0.010 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2002 | 10 | 0.010 |
Why?
|
| Cues | 1 | 2006 | 654 | 0.010 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2003 | 200 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2009 | 2798 | 0.010 |
Why?
|
| Diet | 1 | 2003 | 513 | 0.010 |
Why?
|
| Research Design | 1 | 2004 | 729 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2007 | 2550 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2003 | 2083 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 1293 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2002 | 7028 | 0.010 |
Why?
|